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ABSTRACT  
Background 
To investigate symptoms, clinical factors and socio-demographic factors associated with colorectal cancer 
(CRC) diagnosis and time to diagnosis.  
Methods 
Prospective cohort study of participants referred for suspicion of CRC in two English regions.  Data were 
collected using a patient questionnaire, primary care and hospital records. Descriptive and regression analyses 
examined associations between symptoms and patient factors with: Total Diagnostic Interval (TDI), Patient 
Interval (PI), Health System Interval (HSI), stage.  
Results 
2,677 (22%) participants responded; after exclusions, 2,507 remained. 6.1% were diagnosed with CRC (56% 
late stage), 2.0% with other cancers, 91.9% with no cancer. Half the cohort had a solitary first symptom (1332, 
53.1%); multiple first symptoms were common. In this referred population rectal bleeding was the only initial 
symptom more frequent among cancer than non-cancer cases (34.2% vs 23.9%, p=0.004). There was no 
evidence of differences in TDI, PI or HSI for those with cancer versus non-cancer diagnoses (median TDI CRC 
124 vs non-cancer 138 days, p=0.142). First symptoms associated with shorter TDIs were rectal bleeding, 
change in bowel habit, ‘feeling different’ and fatigue/tiredness. Anxiety, depression and gastro-intestinal co-
morbidities were associated with longer HSIs and TDIs.  Symptom duration-dependent effects were found for 
rectal bleeding and change in bowel habit. 
Conclusion 
Doctors, as well as patients, respond less promptly to some symptoms of colorectal cancer than others.  
Healthcare professionals should be vigilant to the possibility of CRC in patients with relevant symptoms and 
mental health or gastro-intestinal comorbidities. 
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INTRODUCTION 
Colorectal cancer (CRC) is the third most common cancer world-wide and the UK’s fourth commonest 
(CancerResearchUK). Despite the introduction of screening programmes in many countries, most cases 
present symptomatically.  Although five-year survival rates for CRC have improved to over 60% in the last 
decade, CRC patients in the UK continue to have poorer survival rates than those in comparable countries 
(Allemani et al., 2015, Coleman et al., 2011). This may partly be due to longer intervals between the onset of 
cancer symptoms and the patient’s presentation to healthcare, compounded by unequal access to optimal 
diagnostics and specialist care, leading to more late stage diagnoses (Maringe et al., 2013, Neal and Allgar, 
2005). There are also gender, age and region differences in time to diagnosis across the UK (Din et al., 2015).  
The diagnostic process comprises a series of stages or intervals, each contributing to the overall period of time 
between onset of symptom/s and initiation of treatment (Weller et al., 2012). The Total Diagnostic Interval 
(TDI) comprises the Patient Interval (PI- from first symptom onset to first healthcare consultation) and the 
Health System Interval (HSI- from first consultation via referral and investigations to diagnosis and initiation of 
treatment) (Weller et al., 2012): shorter PIs and HSIs are associated with improved CRC prognoses (Neal et al., 
2015, Torring et al., 2011). For CRC, recent evidence suggests that both intervals are longer than for other 
common cancers such as lung or urological cancer (Keeble et al., 2014, Neal et al., 2014a, Dregan et al., 2013, 
Lyratzopoulos et al., 2015b). 
CRC patients may be symptomatic for many months before presentation. They may experience multiple 
symptoms, both bowel-specific (rectal bleeding, change in bowel habit, abdominal pain) and systemic (loss of 
weight or appetite, fatigue) (Rasmussen et al., 2015, Hamilton et al., 2005). Not all individuals interpret their 
initial symptoms as serious, and may attribute them to normal variation, aging, lifestyle or other 
comorbidities (N Hall, 2015, McLachlan et al., 2015, Macleod et al., 2009). International comparisons suggest 
that lower age-related risk and highest perceived barriers to symptomatic presentation were reported in the 
UK (Forbes et al., 2013); other potential influences include negative beliefs about cancer outcomes (Beeken et 
al., 2011) (Lyratzopoulos et al., 2015a) and poor awareness of the risk of cancer (Quaife et al., 2014, Simon et 
al., 2010). 
Once the decision to seek medical help has been made, further delays may occur. One third of CRC patients 
have three or more consultations with a general practitioner (GP) prior to referral, compared with only 17.9% 
for all  cancers (Lyratzopoulos et al., 2013). Furthermore, the pathway to diagnosis in primary care may be 
complex, with delays arising when presentation is complicated by comorbid conditions, when referral is 
delayed or declined, or from false-negative investigation (Rubin et al., 2014). 
Symptoms of possible CRC much more commonly arise from benign or self-limiting conditions, and GPs face a 
considerable challenge to evaluate patients whilst making efficient use of hospital-based resources (Hansen et 
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al., 2015). Much of the evidence about the predictive value of symptoms for cancer or their association with 
later diagnosis comes from retrospective studies of people with CRC (Esteva et al., 2013) or from general 
practice datasets (Hamilton et al., 2005); these are limited by quality of data recording.  Little is known about 
the diagnostic pathways of those whose symptoms transpire not to be caused by CRC or about which 
symptoms are associated with less timely diagnosis. We therefore recruited a prospective cohort of patients 
with symptoms suggestive of CRC at the point of their referral. We aimed to investigate the symptoms, clinical 
factors and socio-demographic factors associated with CRC diagnosis and time to diagnosis. 
 
METHODS  
Setting & governance 
We recruited patients from four secondary care hospitals in the East (n=1) and North East of England (n=3) 
between December 2010 and March 2013.  We gained all appropriate NHS ethics (reference: 10/H0306/50) 
and clinical governance approvals. The SYMPTOM colorectal study was conducted alongside the SYMPTOM 
lung and pancreas studies, collectively part of the NIHR-funded DISCOVERY programme of applied research. 
The methods of data collection and analysis have already been described with the reporting of the SYMPTOM 
lung study (Walter et al., 2015) so will be outlined briefly here. 
Patient recruitment 
All GP referral letters to urgent and routine colorectal and gastrointestinal clinics in participating hospitals 
were reviewed by a research nurse, in order to identify patients aged ≥40 years whose referral mentioned any 
one or more symptoms from a pre-specified list of symptoms known to be associated with CRC (Appendix A). 
These patients were sent an information sheet, the SYMPTOM colorectal questionnaire, and a reply-paid 
envelope for return.  Patients were not eligible for the study if they were already undergoing treatment for 
any cancer (excluding non-melanotic skin cancer), or had such serious mental and/or physical disease that 
they were not considered suitable to complete a questionnaire, based on review of the medical record by the 
research nurse. Patients referred as a result of participation in the Bowel Cancer Screening Programme were 
excluded. No reminder letters were sent to non-responders, as required by the research ethics committee. 
Data collection 
We based our data collection, analysis and reporting on the Aarhus statement for the conduct of cancer 
diagnostic studies, and STROBE guidelines for reporting observational studies (von Elm et al., 2007, Weller et 
al., 2012).  
Patient data 
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Patient data was collected using the SYMPTOM questionnaire, completed and returned to the research team 
within three months of being sent it; most completed it within 2 weeks and before receiving their diagnosis. 
The SYMPTOM colorectal questionnaire was derived from the previously-validated C-SIM questionnaire (Neal 
et al., 2014b). This had been developed for use among people recently diagnosed with cancer, and so we 
modified it for use before diagnosis, consulting widely with clinical and research colleagues and patient 
representatives to ensure it was worded sensitively, since cancer may not have been explicitly mentioned as a 
possibility by the referring GP.  The questionnaire asked for the first symptom noticed by the participant, and 
then sought the presence or absence of specific symptoms (Appendix B). The remaining sections contained 
items about other symptoms and patient factors, including demographic characteristics and comorbidities.   
Primary care data 
Participants’ GPs completed a short proforma from the patient’s clinical record, including dates of the first 
presentation with any symptom from the questionnaire within the previous two years, plus its duration, if 
recorded.  
Hospital data 
We extracted data from hospital medical records on: date and type of referral (urgent, routine, emergency, 
other); date of first specialist consultation; dates of investigations and their findings; date of diagnosis 
(histological, clinical), and dates of MDT meetings and their clinical decisions. Data extraction took place a 
minimum of 6 months after recruitment to allow sufficient time for completion of investigation and initiation 
of treatment.  We undertook double data abstraction of a 5% sample of selected hospital data (dates of 
referral, first appointment, diagnosis, stage) and confirmed an acceptable level of agreement (>80% for dates, 
>90% for diagnosis and stage, Cohen’s Kappa>0.75 for all), with any discrepancies generally minor. 
 
Data handling  
Clinical outcomes 
We used the date on the first confirmatory histology report as the date of diagnosis when this was available 
for both cancer (ICD codes C18-C20), and non-malignant conditions (Weller et al., 2012). Otherwise we used 
the first date of the clinical diagnosis in the hospital medical record.  Participants were classified into three 
groups: those with primary CRC (CRC), other intra-abdominal cancer (OC) and no cancer (NC).  The main 
analyses focused on CRC vs NC, with secondary analyses including all cancers (CRC plus OC) vs NC. CRC staging 
was categorised using TNM status at diagnosis (Travis et al., 2011), and further categorised into Early Stage 
(stages I and II) and Late Stage (stages III and IV). Complex diagnoses, or cases with incomplete data, were 
agreed by an adjudication group of clinicians associated with the study (FW, JE, GR, MR).   
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Demographic and clinical variables 
Demographic details included: gender; age (treated as a continuous variable); ethnicity (coded as white vs 
non-white); smoking status; educational status; occupational status; living alone; and postcode, used to assign 
groups to quintiles of the Index of Multiple Deprivation (IMD) (1 ‘least deprived’ to 5 ‘most deprived’). Clinical 
variables relating to comorbidities included: gastro-intestinal disease (inflammatory bowel disease, irritable 
bowel syndrome, peptic ulcer); respiratory disease (Chronic Obstructive Pulmonary Disease /asthma/other 
lung disease), anxiety/depression, heart disease, diabetes, arthritis. Family history of cancer was also 
identified (present vs absent).  
Symptoms 
All symptoms reported up to two years before diagnosis were entered into the analysis (symptoms of longer 
than 2 years duration were unlikely to be associated with the subsequent diagnosis) (Biswas et al., 2015) 
(Hamilton et al., 2005). Where participants provided estimated dates, these were converted to exact dates by 
adapting an algorithm used in the C-SIM trial (Neal et al., 2014b, Walter et al., 2015). We used exact dates 
where available and estimated dates otherwise. Furthermore, if a participant’s unprompted, or free text, first 
symptom matched their response to a question about specific symptoms, they were given the corresponding 
symptom code and the earlier date. A first symptom was thus identified for each participant. Many 
participants reported more than one first symptom, termed ‘multiple first symptoms’. ‘Subsequent 
symptoms’ were defined as any symptom occurring after a first symptom and prior to diagnosis. 
The total diagnostic interval  
The total diagnostic interval (TDI), or ‘time to diagnosis’, was defined as the time from onset of the first 
symptom/s to the date of diagnosis. Where the date of first presentation to healthcare was known, the 
Patient Interval (PI), defined as the time from first symptom/s to the first presentation, and the Health 
System Interval (HSI), defined as the time from first presentation to diagnosis, were also calculated. 
 
Analysis  
Descriptive analyses were performed on all demographic, clinical and symptom data for the group as a whole, 
and by diagnostic group (CRC, all cancer (CRC plus OC), NC). The CRC group was also sub-analysed by stage at 
diagnosis. The TDI and PI for each group was compared using Wilcoxon rank-sum test. 
Clinically relevant demographics, comorbidities, first symptom/s, and family history of cancer variables were a 
priori included in multivariate analyses to identify predictors of time to diagnosis. Variables present in fewer 
than ten participants were excluded. We chose to analyse CRC, OC and NC groups together for all outcomes 
because at the time of presentation and referral the final diagnosis was unknown. Flexible parametric survival 
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models were used to model time to diagnosis, the PI and the HSI. In these cases, rather than death, the event 
considered to be “failure” in the survival model is either first presentation to healthcare or diagnosis as 
appropriate.  We preferred flexible parametric survival models (Lambert, 2009) over the Cox model as they 
allow the investigation of duration-varying effects. We present results from two models: firstly, with only 
time-constant effects and secondly, one that allows for duration-varying effects for symptoms. The former 
model provides average hazard ratios over time for all variables similar to a Cox model and makes it easier to 
compare the effects of different factors. The second model allows us to examine in more detail how their 
effect varies with duration. Symptoms with duration-varying effects were identified using a forward selection  
approach described in Royston & Lambert (Royston, 2011) and using a significance level of p≤0.01. All models 
used splines with five degrees of freedom for the baseline hazard; the duration-dependent effects were 
modelled using two degrees of freedom for the TDI and HSIs and three degrees of freedom for the PIs.  
 
Sample size 
The expected total number of cases in the two areas was 265 annually. Assuming half of these could be 
identified prospectively from fast track and routine referrals including via colonoscopy (Barrett and Hamilton, 
2008), we needed to recruit for 2 years to achieve 200 participants with CRC. We estimated one patient in 25 
would have CRC (6-11% in 2-week wait clinics (Rai and Kelly, 2007), but lower out with these clinics). With 200 
participants with CRC and at least 10 times as many without we would have over 80% power to detect and 
OR>1.52 for a common symptom occurring in half of participants. With the same 2200 patients all of which 
having a TDI we would expect to have 80% power to detect a HR>1.23 for a symptom occurring in 10% of 
patients. 
 
RESULTS  
12,236 patients were approached and 2,667 responded, an overall 21.8% response rate (East 26.3%, North 
East 18.6%). Of these, 70 did not meet the eligibility criteria, and a further 90 had insufficient data for 
analysis, leaving a final cohort of 2,507 participants. The demographics of the responders were similar to 
those of non-responders (responders 47% male, median age 65; non-responders 45% male, median age 65). 
The stage distribution for those of our cohort who had CRC was comparable to 2013 data for England (late 
stage 50% vs early 40% and 10% unknown) (NCIN).  
The characteristics of the whole cohort are provided in Tables 1 and 2. 152 (6.1%) participants were 
diagnosed with CRC, 50 (2.0%) with other cancers, and 2,305 (91.9%) with no cancer.  The majority of those 
with CRC had late stage disease (n=85, 55.9%; early stage: n=65, 42.8%); two CRCs (1.3%) were unstaged.  The 
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proportion of males was higher in the group diagnosed with CRC compared to the group diagnosed with no 
cancer (57.2% vs 46.2%, p=0.008). Those in the CRC group also had a higher median age (71 vs 65, p<0.001), 
and were more likely to have been referred through an urgent pathway (90.1% vs 71.1%, p<0.001).  The 
diagnostic groups were otherwise similar in terms of deprivation, education and ethnicity (Table 2). 
Among the total cohort, over half had a solitary first symptom (1332, 53.1% (CRC 92, 60.5%, NC 1218, 52.8%). 
However, multiple first symptoms were common with 21.6% having two first symptoms, 9.3% having three, 
and 8.4% with four or more multiple first symptoms. 7.6% reported no symptoms first appearing within 2 
years of diagnosis (most had symptom pre-dating the 2 year cut-off). Across the total cohort, change in bowel 
habit (62.8%) and ‘bleeding from back passage’ (37.8%) were the most common symptoms, but only 45% and 
24.4% of those respectively were reported as first symptoms (Table 3).  Symptoms not specifically enquired 
for in the questionnaire but volunteered, such as acute gastro-intestinal illness, perianal pain, flatulence, 
bloating, and mucus discharge, were individually reported by fewer than 3% of participants.  ‘Bleeding from 
back passage’ was significantly more frequently reported in people diagnosed with CRC than non-cancer as a 
first symptom (34.2% vs 23.9%, p=0.004). No other symptom as a first or subsequent symptom was more 
common in those with CRC than those without.  
A TDI could be calculated for 2,316 participants; the median TDI across the whole cohort was 136 days (IQR 
74-255) (Table 4). There was no difference in the TDI between people diagnosed with CRC and no cancer (CC 
124 vs NC 138 days, p=0.142, and no evidence of differences between PI and HSI among those with and 
without CRC (PI median 41 days vs 36 days, p=0.606; HSI 49 days vs 59 days, p=0.078).   
Results from the time constant survival models are shown in Table 5 (supplementary Table A1 for univariate 
analyses). Older age at diagnosis and a number of symptoms were all associated with a shorter TDI while GI 
comorbidity, depression/anxiety, and family history of cancer were all associated with a longer TDI and HSI.   
Symptom duration-dependent effects 
We found symptom duration-dependent effects for ‘bleeding from back passage’ and change in bowel habit 
(supplementary Figure 1). The time-constant effects from other variables in the same model are similar to 
those described in the previous section and are not detailed here. The symptom ‘bleeding from back passage’ 
was associated with briefer PI and HSIs initially (HR>1), but as the duration of this symptom lengthened the 
association weakened (HR became close to 1). In other words, when this symptom was present it was 
associated with faster action (presentation to healthcare professional and/or referral) in the initial period 
following symptom onset or presentation, compared to other symptoms, but if initial action was not taken the 
existence of the symptom had little impact on action at later times.  In contrast, a change in bowel habit was 
associated with a lengthier PI initially (HR<1) but if the symptom persisted beyond 10 days it became 
associated with a briefer PI (HR>1). In other words, those whose initial symptom was a change in bowel habit 
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were less likely to present early than those with other symptoms, but of those who did not present in the first 
10 days, they presented faster on average than people with other symptoms (HR>1).  Change in bowel habit 
was always associated with a briefer HSI, with no time-dependent effect.  
For early stage CRC, the median TDI for any first symptom was 157 days compared with 99 days for late stage 
CRC (p=0.019) (Table 6). 
 
DISCUSSION  
This is the first study worldwide to recruit a large prospective cohort of patients with suspicious symptoms 
before diagnosis in order to study factors associated with time to diagnosis for CRC.  Among these patients, 
who had been referred for investigation, rectal bleeding was the only symptom more frequently seen with 
CRC, but it occurred in only a third of cases as a first symptom and less than two thirds at any point prior to 
diagnosis.  Other so-called ‘alarm’ symptoms such as change in bowel habit were also very common in this 
referred population but did not differentiate between CRC and those without cancer. The positive predictive 
value of these symptoms will be higher in this study population than in primary care, but the odds ratio 
between those with and without cancer will fall as this is an enriched, referred population. This doesn’t mean 
these symptoms should not be taken seriously. Multiple first symptoms were common, and symptoms often 
evolved over time before patients sought health care. There were different symptom and patient factors 
associated with the PI and HSIs.  Some less specific symptoms such as indigestion/abdominal pain or ‘feeling 
different’ were associated with shorter PIs; in contrast, only the very specific, ‘classical’, symptoms such as 
change in bowel habit and rectal bleeding were associated with shorter HSIs.  
Our novel analysis of duration-dependent effects of symptoms showed different patient and healthcare 
provider responses to certain key symptoms of CRC according to how long the patient had, compared to other 
symptoms, experienced them.  A short duration of rectal bleeding for some patients triggers an early 
consultation and prompt response by the health care system.  Once rectal bleeding has been present for a 
longer time it is no more likely than other symptoms to have a shorter diagnostic interval despite its 
recognition as a classical alarm symptom.  This means that both patients and healthcare providers may 
normalise longer-term rectal bleeding and not consult or investigate promptly (Emery et al., 2013).   
Comorbidities in the whole cohort were also associated with longer total diagnostic and healthcare intervals.  
Importantly, people with mental health problems, self-reported anxiety or depression, experienced a longer 
TDI and HSI, suggesting that their possible physical symptoms were not taken as seriously and were 
investigated later. Similarly, gastro-intestinal comorbidity increased time to diagnosis, probably due to health 
care providers attributing new or worsening symptoms to pre-existing illness (Emery et al., 2013, N Hall, 
2015).    
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There was no evidence that those with CRC were diagnosed more quickly than those with an alternative 
diagnosis. This is surprising given the fact that there were a higher proportion of cancers utilising the urgent 
pathway, and guidance on urgent referral for suspected CRC in England recommends that ‘alarm’ symptoms 
such as rectal bleeding and change in bowel habit  warrant urgent referral for investigation (NICE, 2005).  
Symptoms other than rectal bleeding in this relatively large prospective cohort did not help differentiate CRC 
from other diagnoses.  
The median PI was 35 days and median HSI (combining primary and secondary care) was 58 days. This 
contrasts with findings of the secondary analysis of CRC data in the National Audit of Cancer Diagnosis in 
Primary Care, where data from primary care medical records showed a median PI of 19 days (Lyratzopoulos et 
al., 2015b). In a separate study utilising the same dataset, 21% of CRC patients had 3 or more primary care 
consultations prior to referral, potentially contributing to longer HSIs (Lyratzopoulos et al., 2013).  However, in 
an analysis of UK General Practice Research Database data for 2962 patients with CRC in 2007/8, the median 
HSI, of 80 days, was more comparable to our own findings (Neal et al., 2014a). 
Key strengths of this study were the prospective design and the collection of data from several sources: 
patient reports, and primary care and specialist records. The analytical and reporting approaches were robust 
and performed according to the methodological approaches and definitions recommended in the Aarhus 
statement (Weller et al., 2012) and STROBE guidelines (von Elm et al., 2007).  We chose to define the date of 
first symptom/s using the patient-reported date rather than the primary care-reported date, as we were 
analysing patient-reported symptom/s.  Ideally, a study would recruit patients from primary care before 
referral; however, this would be accompanied by major logistical and resource implications in identifying an 
extremely large prospective cohort of patients with colorectal symptoms in order to capture sufficient 
patients with cancer.  Instead, we recruited patients when they first encountered secondary care; this had the 
added benefit of allowing us to recruit patients presenting as emergencies, and those referred from other 
specialists.  Recruitment involved two regions of England, selected to ensure a broad range of socio-
economic, educational and occupational levels, and the deprivation data suggest that the cohort was 
reasonably representative of the national population.  
The main study limitation is the overall recruitment rate of 22%, though this is similar to other recent studies 
(Kidney et al., 2015, Walter et al., 2015). We sought to make contact with the target population before they 
underwent investigation and received a diagnosis, and it is possible that some were unable or unwilling to 
complete a questionnaire at this worrying time.  We are also likely to have under-recruited people who 
presented as an emergency or who died soon after presentation. However, a recent study from the English 
Cancer Patient Experience Study showed that only 6% of eligible patients died between sampling and mail-out 
suggesting potential survival bias in these types of study is relatively small (Abel et al., 2016).  The 
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demographics of non-responders were very similar to participants, and the proportion of late stage CRC was 
comparable to national data, suggesting our cohort was reasonably representative, that selection bias was not 
a major issue, and that the findings can be generalised to similar symptomatic populations. If sicker patients 
were less likely to take part in the study, and they were more likely to have shorter intervals, we may have 
overestimated the typical intervals in the population. We may well have also underestimated differences 
between those with different presenting symptoms. In common with a Danish prospective population-based 
study of diagnostic intervals, the problem of confounding by indication remains to some extent (Torring et al., 
2012). Our results did not find that shorter time to diagnosis was associated with earlier stage disease.  It may 
be that late stage disease has different symptom profiles which affect help-seeking and use of diagnostic 
pathways. Tumour factors (such as histological type, rate of growth and location) and host factors (such as 
comorbidity) can influence diagnostic intervals and result in apparently earlier diagnosis of later stage disease. 
As our study set out to investigate the diagnostic intervals from perception of first symptom to diagnosis, our 
primary exposure was the initial symptom or symptoms.  While this approach allows us to make robust 
comparisons with other findings, it may obscure the finer detail of symptom patterns and clusters as they 
evolve over time, and their effects on timely help-seeking by patients and timely diagnosis in primary and 
secondary care. Although this was a large cohort, we had insufficient power to examine specific clusters of 
symptoms and their associations with outcomes; a much larger prospective study would be required to 
achieve this. The fact that fewer CRC cases were recruited than was the aim meant that the study was only 
powered to detect large differences in symptoms between those with and without CRC.  
This study shows that there are subtle differences in the impact of symptoms and patient factors on patient 
and healthcare intervals, with some clear implications for policy makers and clinicians. Although rectal 
bleeding was the only symptom predictive of CRC in this referred population it was only reported as the first 
symptom in one third of cases and as a subsequent symptom in a further 25% of cases. Despite conducting 
such a large prospective cohort study we failed to identify any other strong solitary symptom signals of CRC, 
suggesting that bowel cancer awareness campaigns which currently concentrate on a single symptom should 
also consider messages that reflect the importance of multiple symptoms and evolution of symptoms over 
time (Moffat et al., 2015).  The recently revised NICE guidelines for early detection of CRC support this 
premise, and have also lowered the threshold for referral, in line with patient preferences for investigation 
(Banks et al., 2014a, Banks et al., 2014b).  However, our study has also shown that only people presenting 
with shorter histories of rectal bleeding are investigated promptly, and that health care professionals should 
remain alert to symptoms of possible CRC in people with a history of gastro-intestinal or mental health 
conditions.  The increasingly widespread use of clinical decision support in primary care can also be informed 
by our findings (Dikomitis et al., 2015, Green et al., 2015), but further research is needed, alongside GPs and 
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specialists, to identify mechanisms by which patients can be identified, referred and diagnosed in the most 
timely and appropriate way. 
In conclusion, as efforts to expedite the diagnosis of symptomatic colorectal cancer are likely to have benefits 
for patients in terms of improved survival, earlier-stage diagnosis and improved quality of life, it continues to 
be a priority to identify symptoms and other factors which should prompt an individual to seek help or a GP to 
refer in an appropriate and timely manner. It is also important to develop other strategies for earlier 
diagnosis, including increasing uptake of CRC screening and perhaps the development of biomarkers to 
improve early detection. Nevertheless, these data provide support for more targeted evaluation of suspicious 
symptoms in an attempt to identify CRC at an earlier and more amenable stage. It may also be that targeted 
interventions at higher risk populations aimed at symptom monitoring could be more effective at recognising 
symptom evolution.   
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Appendix A Inclusion-exclusion recruitment criteria 
(i) Fast/urgent clinic track referrals and emergency admissions: include ALL. 
(ii) Routine referrals (and via colonoscopy): Include patients with      
• Change in bowel habit (including diarrhoea or constipation) 
• Rectal bleeding/ blood in stool 
• Abdominal pain (in presence of weight loss) 
• Abdominal mass  
• Anaemia 
• Expressed concern about possibility of cancer 
Exclude: 
• Review of established diagnosis where there is no cancer concern 
• Previous GI cancer 
• Known infective diarrhoea (e.g. after recent foreign travel) 
• Abdominal pain in the absence of weight loss  
 
Appendix B  
The questionnaire starts with: ‘We are interested in symptoms which you think are related to your recent 
referral to hospital.  The following questions are about when you first noticed a symptom and when you first 
told your GP or nurse about it.  Please give an exact date if you can.  Otherwise please give your best estimate 
(for example, approximately how long ago, the month or the season).  You may wish to refer to your diary or 
calendar if you have it with you’. The first question was: ‘What was the first thing or symptom you noticed 
that made you think something might be wrong?’  Eight specific symptoms followed: change in bowel habit; 
‘bleeding from the back passage’; back pain; indigestion or abdominal pain ‘that wasn’t normal for you’; plus 
decrease in appetite, unexplained weight loss, fatigue or tiredness ‘that is unusual for you’, and feeling 
different ‘in yourself’ from usual. 
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Table 1: Diagnostic characteristics of participants 
 
 
Total (%) 
Primary Colorectal Cancer 152 (6.1) 
Other Cancers: 50 (2.0) 
Lymphoma 9 
Prostate cancer 7 
Gynaecological cancer (ovarian, uterine) 7 
Anal  cancer 5 
Renal  cancer (kidney, bladder) 4 
CUP 4 
Oesophageal cancer 3 
Pancreatic cancer 2 
Multiple myeloma 2 
Stomach cancer 2 
Other
1
 5 
Non Cancer
1
: 2305 (91.9) 
Polyps 612 (26.6) 
Polyp with metaplasia 200 (8.7) 
Poly with dysplasia 168 (7.3) 
Polyp NOS  244 (10.6) 
Ni l  abnormal 598 (25.9) 
Diverticular disease 463 (20.1) 
Inflammatory Bowel Disease (IBD) 189 (8.2) 
Col i tis ulcerative 55 (2.4) 
Col i tis - other 99 (4.3) 
Crohn's Disease 7 (0.3) 
IBD NOS 28 (1.2) 
Haemorrhoids 186 (8.1) 
Irritable Bowel  Syndrome 95 (4.1) 
Benign gastro-duodenal disease 83 (3.6) 
Miscellaneous 51 (2.2) 
Anaemia (no lower GI cause found) 31 (1.3) 
Hepato-pancreato-biliary disorders 20 (0.9) 
Anal  conditions (excluding haemorrhoids) 13 (0.6) 
Constipation 13 (0.6) 
Coel iac disease 5 (0.2) 
Total 2507 
Notes:  
1) Percentages add to more than 100% because 54 patients have more than one diagnosis. More than one diagnosis in the 
same category (e.g. miscellaneous) was counted only once. 
2) Other cancers include (n=1): leiomyosarcoma, appendix, peritoneal, melanoma, cholangiocarcinoma, 
CUP=Cancer Unknown Primary, including one diagnosed as ‘metastatic’, NOS=not otherwise specified 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Socio-demographic characteristics of participants 
Values are n (%) unless otherwise stated 
 
 
 
Colorectal Cancer  
(CRC) 
(n = 152) 
Other Cancer 
(OC) 
(n = 50)  
No Cancer 
(NC) 
(n = 2305) 
Total  
Cohort1 
(n = 2507) 
p-value 
CRC vs NC 
Gender  
Male  
Female  
87 (57.2) 
65 (42.8) 
30 (60) 
20 (40) 
1064 (46.2) 
1241 (53.8) 
1181 (47.1) 
1326 (52.9) 
0.008 
Age (median, range)  
 71 (40-92) 71.5 (51-91) 65 (40-100) 65 (40-100) <0.001 
Highest education level   
Degree/Diploma/equivalent 
A Level/GCSE/O Level 
Other/None/missing 
67 (44.1) 
42 (27.6) 
43 (28.3) 
17 (34.0) 
16 (32.0) 
17 (34.0) 
941 (40.8) 
740 (32.1) 
624 (27.1) 
1025 (40.9) 
798 (31.8) 
684 (27.3) 
0.511 
Ethnicity  
White 
Other/missing 
149 (98.0) 
3 (2.0) 
50 (100) 
0 
2259 (98.0) 
46 (2.0) 
2458 (98.1) 
49 (2.0) 
0.640 
Smoking status  
Current 
Ex-smoker 
Never/missing 
16 (10.5) 
68 (44.7) 
68 (44.7) 
2 (4.0) 
21 (42.0) 
27 (54.0) 
205 (8.9) 
970 (42.1) 
1130 (49.0) 
223 (8.9) 
1059 (42.2) 
1225 (48.9) 
0.549 
Lives alone  
Yes 
No/missing 
43 (28.3) 
109 (71.8) 
14 (28.0) 
36 (72.0) 
538 (23.3) 
1767 (76.7) 
595 (23.7) 
1912 (76.3) 
0.164 
Deprivation (IMD- quintiles)  
1st National Quintile (least) 
2nd National Quintile 
3rd National Quintile 
4th National Quintile 
5th National Quintile (most) 
missing 
61 (40.1) 
40 (26.3) 
12 (7.9) 
20 (13.2) 
19 (12.5) 
0 
13 (26.0) 
12 (24.0) 
10 (20.0) 
10 (20.0) 
5 (10.0) 
0 
826 (35.8) 
550 (23.9) 
352 (15.3) 
304 (13.2) 
263 (11.4) 
10 (0.4) 
900 (35.9) 
602 (24.0) 
374 (14.9) 
334 (13.3) 
287 (11.4) 
10 (0.4) 
0.168 
Referral route  
Urgent 
          GP FT 
          A&E 
          Other 
Non-urgent 
137 (90.1) 
124 (90.5) 
6 (4.4) 
7 (5.1) 
15 (9.9) 
44 (88.0) 
42 (95.5) 
1 (2.3) 
1 (2.3) 
6 (12.0) 
1638 (71.1) 
1597 (97.5) 
14 (0.9) 
27 (1.6) 
667 (28.9) 
1819 (72.6) 
1763 (96.9) 
21 (1.2) 
17 (0.9) 
688 (27.4) 
<0.001 
Region 
Cambridge 
North East 
78 (51.3) 
74 (48.7) 
21 (42.0) 
29 (58.0) 
1109 (48.1) 
1196 (51.9) 
1208 (48.2) 
1299 (51.8) 
0.444 
 
Missing values were included in the Other/Never categories where possible. Percentages are as follows: Employment 
Status (2.0), Education Level  (3.3), Ethnicity (0.8), Smoking Status (1.5), Live Alone (0.6), referral route (2.2).  
  
Table 3: Symptoms reported by participants, stratified by all and first symptom/s and diagnostic group  
Values are n (%) unless otherwise stated, and all columns add up to >100% because of multiple symptoms.  
 
Symptom 
Colorectal Cancer 
(CRC) 
(n = 152) 
No Cancer 
(NC) 
(n = 2305) 
Total 
Cohort 
(n = 2507) 
P-value for 
first 
symptoms 
CRC vs NC 
Symptoms in questionnaire 
First 
symptoms 
Subsequent 
symptoms 
First 
symptoms 
Subsequent 
symptoms 
First 
symptoms 
Subsequent 
symptoms 
 
Change in bowel habit   66 (43.4) 27 (17.8) 1043 (45.2) 410 (17.8) 1129 (45) 446 (17.8) 0.661 
‘Bleeding from back passage’ 52 (34.2) 39 (25.7) 552 (23.9) 296 (12.8) 612 (24.4) 336 (13.4) 0.004 
Indigestion or heartburn or persistent tummy ache that 
wasn’t normal for you 
30 (19.7) 13 (8.6) 509 (22.1) 281 (12.2) 549 (21.9) 302 (12) 0.499 
Fatigue or tiredness that is unusual for you 35 (23) 23 (15.1) 404 (17.5) 307 (13.3) 448 (17.9) 347 (13.8) 0.086 
Feeling different “in yourself” from usual  27 (17.8) 11 (7.2) 391 (17) 257 (11.1) 433 (17.3) 278 (11.1) 0.799 
Decrease in appetite 15 (9.9) 16 (10.5) 195 (8.5) 192 (8.3) 220 (8.8) 221 (8.8) 0.547 
Back pain 3 (2) 9 (5.9) 197 (8.5) 179 (7.8) 210 (8.4) 194 (7.7) 0.004 
Unexplained weight loss 6 (3.9) 18 (11.8) 111 (4.8) 183 (7.9) 127 (5.1) 214 (8.5) 0.626 
Other symptoms reported by participants        
Other (non-gastro-intestinal) symptoms 4 (2.6) 3 (2) 47 (2) 16 (0.7) 53 (2.1) 20 (0.8) NA 
Acute gastro-intestinal illness  0 (0) 3 (2) 48 (2.1) 15 (0.7) 49 (2) 18 (0.7) NA 
Perianal pain or discomfort 2 (1.3) 1 (0.7) 37 (1.6) 15 (0.7) 39 (1.6) 16 (0.6) NA 
Wind or flatulence 0 (0) 2 (1.3) 33 (1.4) 11 (0.5) 33 (1.3) 13 (0.5) NA 
Urgency or leakage of bowels 0 (0) 0 31 (1.3) 13 (0.6) 32 (1.3) 13 (0.5) NA 
Bloating 0 (0) 1 (0.7) 26 (1.1) 12 (0.5) 28 (1.1) 14 (0.6) NA 
Mucus or discharge per rectum 0 (0) 2 (1.3) 25 (1.1) 7 (0.3) 25 (1) 9 (0.4) NA 
Pain, non-abdominal 1 (0.7) 0 22 (1) 9 (0.4) 23 (0.9) 9 (0.4) NA 
NA: Not applicable
4 
 
 
Table 4: Total Diagnostic Interval, Patient Interval and Health System Interval for first symptom/s for total cohort and by diagnostic groups P-values for CC 
vs NC with any symptom: (A) TDI p=0.142, (B) PI p=0.606, (C) HSI p=0.078. Similar results were obtained for the comparison between all cancers and NC (data not shown).  
Symptom Total cohort Colorectal Cancer (CC) No Cancer (NC)  
Median (IQR)  n Median (IQR)  n Median (IQR)  n  
(A) TOTAL DIAGNOSTIC INTERVAL (TDI)*  
Any Symptom 136 (74-255) 2316 124 (74-226) 149 138 (74-264) 2120  
Change in bowel habit   113 (69-203) 1129 124 (66-226) 66 112 (70-203) 1043  
‘Bleeding from back passage’ 90 (49-164) 612 88 (47-142) 52 89 (49-173) 552  
Indigestion/heartburn/persistent tummy ache  139 (81-277) 549 125 (80-262) 30 142 (81-283) 509  
Fatigue or tiredness that is unusual for you 143 (86-239) 448 130 (92-189) 35 146 (86-247) 404  
Feeling different “in yourself” from usual  128 (77-216) 433 124 (80-154) 27 130 (76-231) 391  
Decrease in appetite 115 (69-235) 220 98 (64-138) 15 115 (69-269) 195  
Back pain 161 (79-294) 210 98 (92-525) 3 162 (79-295) 197  
Unexplained weight loss 148 (84-333) 127 111 (82-205) 6 159 (86-346) 111  
(B) PATIENT INTERVAL (PI)**  
Any Symptom 35 (7-92) 2103 41 (13-92) 128 36 (7-93) 1932  
Change in bowel habit   42 (14-92) 1106 57 (22-115) 63 42 (14-92) 1023  
‘Bleeding from back passage’ 25 (3-69) 607 29 (6-66) 52 24 (3-69) 547  
Indigestion/heartburn/persistent tummy ache 31 (5-86) 525 28 (7-90) 27 31 (5-90) 488  
Fatigue or tiredness that is unusual for you 31 (7-89) 365 35 (8-65) 26 31 (6-90) 331  
Feeling different “in yourself” from usual  30 (4-76) 377 37 (14-65) 21 30 (3-77) 343  
Decrease in appetite 20 (3-62) 190 33 (8-90) 15 18 (2-62) 166  
Back pain 29 (2-76) 183 41 (37-64) 3 29 (1-88) 172  
Unexplained weight loss 31 (5-92) 115 46 (35-73) 4 31 (2-96) 102  
(C) HEALTH CARE INTERVAL (HCI)**  
Any Symptom 58 (27-128) 2103 49 (26-106) 128 59 (27-129) 1932  
Change in bowel habit   51 (25-99) 1106 47 (28-101) 63 52 (25-99) 1023  
‘Bleeding from back passage’ 41 (19-85) 607 37 (20-60) 52 41 (19-86) 547  
Indigestion/heartburn/persistent tummy ache 76 (34-156) 525 58 (35-151) 27 78 (34-161) 488  
Fatigue or tiredness that is unusual for you 69 (30-146) 365 54 (27-89) 26 70 (29-147) 331  
Feeling different “in yourself” from usual  67 (32-139) 377 61 (38-87) 21 69 (30-144) 343  
Decrease in appetite 60 (31-138) 190 49 (30-63) 15 64 (30-158) 166  
Back pain 88 (35-203) 183 61 (51-461) 3 82 (35-206) 172  
Unexplained weight loss 83 (39-191) 115 33 (16-50) 4 89 (43-202) 102  
5 
 
*As these are median time intervals (rather than mean intervals) there is no expectation that the median TDI will equal the sum of 
median PI and median HSI.  
**The PI and HSI could only be calculated for 2,103 participants (unknown presentation date n=213). Those with an available date of 
presentation had a shorter median TDI (130 days vs 199 days for the remaining cases) 
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Table 5: Predictors of Total Diagnostic Interval (TDI), Patient Interval (PI) and Health System Interval (HIS)  
Hazard ratio estimates are from a flexible parametric survival multivariable model with only time constant effects. Model is adjusted for all variables in table plus ethnicity (non-white vs. 
white), smoking status (current and ex-smoker vs. never), living alone (yes vs. no) and region (North East vs. Cambridge). In this context the hazard ratio represents the relative increase in 
rate of presentation/diagnosis. A hazard ratio of 2 would imply that patients in one group presented/were diagnosed twice as quickly as in the reference group. 
 
 
Total Diagnostic Interval 
(n=2306) 
Patient Interval 
(n=2095) 
Health System Interval 
(n=2095) 
 HR (95 CI) p-value HR (95 CI) p-value HR (95 CI) p-value 
Bleeding from Back Passage 1.79 (1.62-1.98) <0.001 1.41 (1.27-1.57) <0.001 1.56 (1.41-1.72) <0.001 
Change in Bowel Habit 1.55 (1.42-1.69) <0.001 1.04 (0.95-1.13) 0.440 1.55 (1.42-1.70) <0.001 
Back pain 0.99 (0.85-1.14) 0.874 1.20 (1.02-1.40) 0.024 0.86 (0.73-1.00) 0.052 
Indigestion/Heartburn/Tummy Ache 1.00 (0.90-1.10) 0.942 1.17 (1.06-1.30) 0.003 0.84 (0.76-0.93) 0.001 
Decrease in Appetite 1.10 (0.95-1.28) 0.200 1.15 (0.98-1.35) 0.087 1.11 (0.94-1.30) 0.224 
Weight loss 0.90 (0.75-1.09) 0.284 1.00 (0.82-1.22) 0.987 0.81 (0.66-0.99) 0.038 
Fatigue or Tiredness 1.14 (1.02-1.27) 0.021 1.11 (0.98-1.25) 0.096 1.04 (0.92-1.17) 0.549 
Feeling Different 1.21 (1.08-1.35) 0.001 1.25 (1.10-1.41) <0.001 1.01 (0.90-1.14) 0.812 
Gender (ref=Female)       
Male 1.01 (0.93-1.10) 0.739 1.03 (0.94-1.13) 0.535 1.02 (0.93-1.11) 0.731 
Age at diagnosis (10 years) 1.08 (1.04-1.12) <0.001 1.13 (1.08-1.18) <0.001 0.99 (0.95-1.03) 0.698 
IMD (ref=least deprived)  0.611  0.645  0.528 
2nd National Quintile 0.98 (0.88-1.09)  1.03 (0.91-1.15)  0.92 (0.82-1.03)  
3rd National Quintile 1.03 (0.90-1.17)  1.09 (0.95-1.25)  0.94 (0.82-1.08)  
4th National Quintile 0.91 (0.79-1.04)  0.97 (0.84-1.12)  0.90 (0.78-1.04)  
5th National Quintile 0.97 (0.83-1.13)  0.98 (0.83-1.16)  0.96 (0.81-1.13)  
GI Comorbidity 0.80 (0.71-0.89) <0.001 1.01 (0.89-1.14) 0.904 0.78 (0.69-0.88) <0.001 
Depression/anxiety  0.86 (0.77-0.96) 0.007 1.05 (0.93-1.18) 0.415 0.80 (0.71-0.90) <0.001 
Family History of cancer 0.91 (0.83-0.99) 0.031 0.94 (0.86-1.04) 0.237 0.90 (0.82-0.99) 0.033 
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Table 6: Time to diagnosis (days) for first symptom/s among colorectal cancer group, stratified by stage at diagnosis  
P-values for early vs late stage with any symptom: (i) p=0.019, (ii) p=0.022. 
 
 
 
 
 
 
 
 
 
 
 
 
a not staged: 2 
 
 Early Stage 
(n = 64) 
Late Stage 
(n = 82) 
 Median (IQR) n Median (IQR) n 
Any Symptom 157 (93-243) 64 99 (65-198) 83 
Change in bowel habit   159 (92-274) 23 111 (65-173) 41 
‘Bleeding from back passage’ 92 (36-156) 23 84 (47-133) 28 
Indigestion or heartburn or persistent tummy ache 
that wasn’t normal for you 
188 (96-310) 11 103 (62-153) 18 
Fatigue or tiredness that is unusual for you 154 (95-226) 15 110 (81-152) 20 
Feeling different “in yourself” from usual 114 (95-154) 6 101 (65-153) 18 
Decrease in appetite 138 (95-186) 3 83 (56-128) 11 
Back pain - 0 98 (92-525) 3 
Unexplained weight loss 205 (82-572) 3 69 (39-98) 2 
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Table 1: Univariable analysis of factors associated with Total Diagnostic Interval (TDI), Patient Interval (PI) and Health System Interval (HSI) 
Hazard ratio estimates are from flexible parametric survival univariate models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Diagnostic Interval 
N=2316 
Patient Interval 
N=2103 
Health System Interval 
N=2103 
 HR (95 CI) p-value HR (95 CI) p-value HR (95 CI) p-value 
‘Bleeding from Back Passage’ 1.59 (1.45-1.75) <0.001 1.25 (1.14-1.37) <0.001 1.52 (1.38-1.67) <0.001 
Change in Bowel Habit 1.43 (1.32-1.55) <0.001 0.97 (0.89-1.05) 0.424 1.46 (1.34-1.60) <0.001 
Back pain 0.88 (0.76-1.02) 0.081 1.21 (1.04-1.41) 0.015 0.77 (0.66-0.89) 0.001 
Indigestion/Heartburn/Tummy Ache 0.92 (0.84-1.01) 0.091 1.13 (1.02-1.24) 0.017 0.78 (0.71-0.86) <0.001 
Decrease in Appetite 1.07 (0.93-1.23) 0.322 1.33 (1.14-1.54) <0.001 0.99 (0.86-1.15) 0.932 
Weight loss 0.83 (0.70-1.00) 0.047 1.03 (0.86-1.25) 0.726 0.79 (0.66-0.95) 0.015 
Fatigue or Tiredness 0.99 (0.89-1.10) 0.833 1.13 (1.01-1.27) 0.032 0.91 (0.82-1.02) 0.119 
Feeling Different 1.14 (1.02-1.26) 0.017 1.30 (1.16-1.45) <0.001 0.97 (0.86-1.08) 0.538 
Gender (ref=Female)       
Male 1.10 (1.01-1.19) 0.027 1.04 (0.95-1.13) 0.367 1.08 (0.99-1.18) 0.083 
Age at diagnosis (10 years) 1.06 (1.02-1.10) 0.001 1.10 (1.06-1.14) <0.001 1.01 (0.98-1.05) 0.527 
Ethnicity (ref= White)       
Other 0.75 (0.55-1.04) 0.083 0.83 (0.59-1.16) 0.270 0.75 (0.53-1.05) 0.090 
Smoking Status (ref= Never)  0.702  0.236  0.292 
Current 0.94 (0.81-1.10)  1.05 (0.90-1.23)  0.94 (0.81-1.10)  
Ex-Smoker 1.01 (0.92-1.10)  0.94 (0.86-1.03)  1.05 (0.96-1.15)  
Live Alone (ref= No)       
Yes 0.97 (0.88-1.06) 0.468 1.05 (0.95-1.17) 0.306 0.92 (0.83-1.02) 0.098 
IMD (ref=least deprived)  0.644  0.334  0.068 
2
nd
 National Quintile 1.00 (0.90-1.12)  1.05 (0.93-1.17)  1.00 (0.89-1.11)  
3
rd
 National Quintile 1.04 (0.92-1.18)  1.15 (1.01-1.31)  1.02 (0.89-1.16)  
4
th
 National Quintile 1.04 (0.91-1.18)  1.02 (0.89-1.16)  1.06 (0.93-1.22)  
5
th
 National Quintile 1.11 (0.96-1.27)  1.06 (0.92-1.23)  1.23 (1.06-1.42)  
GI Comorbidity 0.76 (0.68-0.85) <0.001 1.05 (0.93-1.18) 0.442 0.73 (0.65-0.82) <0.001 
Depression/anxiety  0.83 (0.75-0.93) 0.001 1.03 (0.92-1.16) 0.560 0.79 (0.70-0.88) <0.001 
Family History of cancer 0.89 (0.82-0.97) 0.011 0.94 (0.85-1.03) 0.157 0.93 (0.84-1.01) 0.098 
Region (ref=Cambridge)       
North East 1.33 (1.22-1.44) <0.001 1.08 (0.99-1.17) 0.093 1.51 (1.38-1.64) <0.001 
  
SUPPLEMENTARY ONLINE MATERIAL 
 
Figure 1: Time dependent effects of ‘bleeding from back passage’ and ‘change in bowel habit’ on the hazard ratio (HR) of Total Diagnostic Interval (TDI), 
Patient Interval (PI) and Health System Interval (HSI) 
 
 
 
 
